Researchers have discovered a new method to fight secondary breast cancers that have been able to spread to the brain

 

A research conducted by researchers from the RCSI the University of Medicine and Health Sciences, as well as the Beaumont RCSI Cancer Centre (BRCC) has identified a possible novel method of treating secondary breast cancers that have been able to spread to the brain making use of existing treatments.

The study, which was published in Nature Communications, was supported through Breast Cancer Ireland with support from Breast Cancer Now and Science Foundation Ireland.

The majority of deaths related to breast cancer are the result of the treatment's relapse, which leads to the spreading of tumors to various organs throughout the body. If secondary breast cancer or metastatic breast cancer develops, it develops in the brain, it can be extremely dangerous, often giving patients just a few months of life.

The RCSI study was focused on tracking genetically the tumor's progression from the initial the diagnosis of breast cancer as primary to metastatic spread within the brain of cancer patients. The study found that more than 50% of tumors showed variations in the method they repaired their DNA which makes the tumors more susceptible to an existing medication known as PARP inhibitor. PARP inhibitors function by blocking cancer cells' ability to repair their DNA, resulting in cancer cells dying.

"There aren't enough treatments for patients suffering from breast cancer that has spread to brain, and research aimed at broadening treatment options is essential. This study is a significant improvement in moving just one step closer a possible treatment for those suffering from this deadly cancerous complication that is a complication of tumors of the breast.," commented Professor Leonie Young as the study's Principal Investigator.

"By uncovering these new vulnerabilities in DNA pathways in brain metastasis, our research opens up the possibility of novel treatment strategies for patients who previously had limited targeted therapy options," said the study's the study's lead author Dr. Damir Vareslija.

Read More

Omicron causes US deaths at a higher rate than the delta wave of fall.

 
A patient is asked to take an swab of their nose for the COVID-19 Polymerase Chain Reaction (PCR) test, while a person is watching during the FEMA's COVID-19 test at a drive-through site on Pima Community College West Campus in Tucson, Ariz. on Monday, January. 24 2022. Omicron is the highly infectious coronavirus strain that has been sweeping across the nation, is driving to keep the American death toll up from in the last delta wave which is likely to increase for days , or even weeks. Credit: Rebecca Sasnett/Arizona Daily Star via AP

Omicron is the highly infectious coronavirus variant that is sweeping the United States, is pushing every day's American death toll up from in the last delta wave and is expected to increase for days , or even weeks.

The seven-day average for new COVID-19 deaths per day across the U.S. has been climbing from mid-November to 2,267 on Thursday , and surpassing the peak of 2,100 in September where delta was the predominant variant.

It is believed that omicron could be the main cause of disease that is circulating across the country. Even though it is a less serious illness for the majority of people, the fact that it's more easily transmitted means that there are more people who are sick and dying.

"Omicron will push us over a million deaths," said Andrew Noymer, a public health professor at the University of California, Irvine. "That will cause a lot of soul searching. There will be a lot of discussion about what we could have done differently, how many of the deaths were preventable."

The daily average death toll is currently at the same amount as month, in February when the nation was beginning to fall off its record-breaking 3,300 per day.

A greater number of Americans are taking precautionary steps to protect themselves from the virus than they did prior to the omicron outbreak as per an survey conducted by AP-NORC in the week of. Many people, exhausted from the crisis are returning to a normal level, hoping that prior vaccinations or previous infections will help protect the virus.

Read More

Nanoparticles in the flu vaccine is a powerful protection. Researchers discover.

 

 A vaccine for influenza that is administered via the nose and made up of nanoparticles that boost immune response gives you a strong defense against different viruses of influenza, as per researchers at the Institute for Biomedical Sciences at Georgia State University.

The intranasal vaccine triggered multiple immune responses that led to strong cross protection for mice against the flu. The vaccine is comprised of nanoparticles made up of PEI-HA/CpG. PEI (polyethyleneimine) is a durable and flexible delivery system, can carry both antigens (hemagglutinin, and HA) that trigger an immune response within the body and adjuvants (CpG) which enhance the body's response to an antigen, thereby enhancing the immune response.

The comprehensive immune response and cross-protection were for a long time, showing protection from influenza for six months following vaccination. The findings were presented in the Journal ACS Applied Materials & Interfaces.

Intranasal vaccination is the best method for treating respiratory infections like influenza. Seasonal influenza vaccines usually trigger weak immune responses that swiftly decrease, leaving people vulnerable to new influenza strains. Innovations in the field of influenza vaccines will be required to safeguard against the wide variety strains of flu virus. Intranasal vaccination is a way to boost local mucosal immune response by preventing influenza-related infections at the point of entry for viruses.

In the influenza virus HA is an important protein which plays an important role in the initial stages of the virus's infection. Influenza is a protein that includes a head region as well as a stalk region. The current influenza vaccines trigger immune responses to the HA head region, however this head region can be highly variable and can result in lower efficiency against various strains. In addition, the HA stalk is considered to be more stable for different strains of influenza viruses.

The antigens of protein that are administered intravenously are typically less likely to trigger an immune response, therefore adjuvants are required to create extremely effective intranasal vaccines. Adjuvants, like CpG are able to enhance and alter immune responses, which can increase the effectiveness and range of protection.

"The PEI-HA/CpG nanoparticles show good potential as a cross-protective influenza vaccine candidate," said Dr. Baozhong Wang, corresponding author of the study as well as a professor at the Institute for Biomedical Sciences at Georgia State. "The mixture with PEI as well as CpG in the nanoparticles PEI-HA/CpG contributed to the multiple immune responses that resulted in a robust cross-protection. The integration in the combination of CpG and antigens within the same nanoparticle increased the immune response of cells.

"Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, or the ability to provoke an immune response, providing cross protection against different influenza virus strains. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups."

"Nanoparticle platforms have shown intriguing characteristics and great potentials in the development of next-generation cross-protective influenza vaccines," stated the researcher Dr. Chunhong Dong, the primary researcher of the study and postdoctoral fellow at the Institute for Biomedical Sciences. "However, challenges exist to the successful research and development of nanoparticle vaccines. Though no apparent adverse effects were observed in the study, a more comprehensive safety evaluation of the nanoparticle adjuvant system is needed before clinical trials."

 

Read More